MyMD Pharmaceuticals Inc (MYMD)

[knuts4oe]

The New England Journal of Medicine sent me an email advertizing a new service they are offering, called "NEJM Catalyst (Innovations in Care Delivery)". On reading their description of the new service, my reaction was that it would be perfect for the coming introduction of MYMD-1.
Ironically, I had recently GOGGLED the most significant medical journals,and NEJM was right up there with the best, and had thought wouldn't it be great if it was the journal that was publishing the healthy life extension rat study.
B and B a tells us that the promised MYMD corporate profile will be broadcast widely soon. So we have this broadly broadcast corporate profile, the release of the preliminary results of the 2 human studies in progress, the publication of the healthy life extension rat study, and a new service from NEJM focussed on "Innovations In Care Delivery", all conviently adding up to a broad introduction by Jonnie and his team, of MYMD's focus of treating medical conditions and diseases rather than just treating symptons!
Perhaps that is why the WSJ website is still showing the one and only investor BUY signal with a price projection of $1,536.00 a share. It was posted last fall, and the price was predicted to be achieved within a year.
Pipe dream! Could be! Hope not!